{"Symbol": "SRPT", "AssetType": "Common Stock", "Name": "Sarepta Therapeutics Inc", "Description": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.", "CIK": "873303", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "215 FIRST STREET, CAMBRIDGE, MA, UNITED STATES, 02142", "OfficialSite": "https://www.sarepta.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "1864164000", "EBITDA": "-36284000", "PERatio": "None", "PEGRatio": "159.25", "BookValue": "12.6", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-2.83", "RevenuePerShareTTM": "24.63", "ProfitMargin": "-0.113", "OperatingMarginTTM": "-0.158", "ReturnOnAssetsTTM": "-0.0152", "ReturnOnEquityTTM": "-0.214", "RevenueTTM": "2413715000", "GrossProfitTTM": "443831000", "DilutedEPSTTM": "-2.83", "QuarterlyEarningsGrowthYOY": "26.64", "QuarterlyRevenueGrowthYOY": "-0.145", "AnalystTargetPrice": "21.43", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "7", "AnalystRatingHold": "14", "AnalystRatingSell": "3", "AnalystRatingStrongSell": "2", "TrailingPE": "-", "ForwardPE": "13.68", "PriceToSalesRatioTTM": "0.772", "PriceToBookRatio": "1.412", "EVToRevenue": "0.938", "EVToEBITDA": "80.2", "Beta": "0.39", "52WeekHigh": "110", "52WeekLow": "10.41", "50DayMovingAverage": "21.15", "200DayMovingAverage": "23.13", "SharesOutstanding": "104787000", "SharesFloat": "99249000", "PercentInsiders": "5.168", "PercentInstitutions": "88.395", "DividendDate": "None", "ExDividendDate": "None"}